

Treatment of TMDs:

Bridging the Gap Between Advances in Research and Clinical Patient Management

Edited by

Charles S. Greene, DDS

Clinical Professor

Department of Orthodontics

College of Dentistry

University of Illinois

Chicago, Illinois

Daniel M. Laskin, DDS, MS

Professor and Chairman Emeritus

Department of Oral and Maxillofacial Surgery

Schools of Dentistry and Medicine

Virginia Commonwealth University

Richmond, Virginia



Quintessence Publishing Co, Inc

Chicago, Berlin, Tokyo, London, Paris, Milan, Barcelona, Beijing, Istanbul,

Moscow, New Delhi, Prague, São Paulo, Seoul, Singapore, and Warsaw

This book is dedicated to the memory of Dr Laszlo Schwartz, who founded the first academic temporomandibular joint (TMJ) center in the United States at Columbia University in 1949. At that time, the generally accepted viewpoint was that abnormalities in dental and jaw relationships were the major factors in the development of disorders related to the TMJ. Therefore, procedures such as occlusal adjustment or major restorative dentistry were the preferred therapies. All this eventually changed as the result of his pioneering research and his leadership. His textbook, *Disorders of the Temporomandibular Joint*, published in 1959, represented a major paradigm shift from a mechanical to a biopsychosocial approach to their treatment. Dr Schwartz's work not only had a profound influence on the future direction of research in the field, but it has also led to improved care of patients with temporomandibular disorders.

Foreword viii

Preface ix

Contributors x

Section I. Understanding Regional and Widespread Pain Phenomena

- 1** **Sensory Mechanisms of Orofacial Pain** 3
Ronald Dubner, Ke Ren, and Barry J. Sessle
- 2** **Pathophysiology of Masticatory Myofascial Pain** 17
Rafael Benoliel, Peter Svensson, and Eli Eliav
- 3** **Pathophysiology of Intracapsular Inflammation and Degeneration** 33
Rüdiger Emshoff
- 4** **Comorbid Conditions: How They Affect Orofacial Pain** 47
Ana Velly, Petra Schweinhardt, and James Friction
- 5** **How Sleep and Pain Affect Each Other** 57
Guido Macaluso, Maria C. Carra, and Gilles J. Lavigne

Section II. Assessing Susceptibility to Pain Development and Chronicity

- 6** **Genetic Determinants of Complex Orofacial Pain Conditions** 69
Christian S. Stohler
- 7** **Quantitative Sensory Testing of Pain Responsiveness** 79
Peter Svensson, Eli Eliav, and Rafael Benoliel
- 8** **Predicting Treatment Responsiveness: Somatic and Psychologic Factors** 91
Richard Ohrbach and Thomas List

Section III. Biomechanics of TMJ Function

- 9** **Biomechanics and Mechanobiology of the TMJ** 101
Sandro Palla and Luigi M. Gallo
- 10** **Finite Element Analysis of the TMJ** 113
Jan Harm Koolstra
- 11** **Lubrication of the TMJ** 123
Yehuda Zadik and Dorrit W. Nitzan

Section IV. Diagnostic Technology

- 12** Imaging of the TMJ and Associated Structures 133
David C. Hatcher
- 13** Brain Imaging of Pain Phenomena 141
Geoffrey E. Gerstner, Eric Ichesco, and Tobias Schmidt-Wilcke
- 14** Synovial Fluid Analysis and Biomarkers of TMJ Disease 155
Regina Landesberg and Sunil Wadhwa

Section V. Therapeutic Advances

- 15** Developmental and Evolutionary Perspectives on TMJ Tissue Engineering 167
David A. Reed, Robert P. Scapino, Callum F. Ross, Di Chen, and Thomas G. H. Diekwisch
- 16** Injectable Compounds to Treat TMJ Pain and Degenerative Joint Disease 177
Songsong Zhu and Jing Hu
- 17** Pharmacologic Management of TMD Pain 185
Stephan A. Schug, Stefan Lauer, and Robert E. Delcanho

Appendix of Abbreviations 195

Index 197

I am very pleased to write a foreword for this textbook. My first reason for this is based on the major shift in the concepts and protocols for managing temporomandibular disorders (TMDs) and orofacial pain that I have seen in my professional career. These changes have occurred as a result of the new knowledge we have gained that has enhanced our understanding of these conditions, and the precise goal of this textbook is to bring this type of information to the clinician. Another reason that I am pleased to write this foreword is because of my admiration for both Dr Greene and Dr Laskin. Very early in the 1970s, these two individuals boldly questioned universally accepted therapies, and their efforts began a professional movement that demanded more evidence to support our TMD treatments. Acquiring such evidence is essential in offering the best care to our patients. This textbook provides the clinician with an understanding of the basic science and clinical research that supports the use of our current therapies while also pointing the way toward future treatment possibilities. These principles are fundamental to good health care.

Many years ago, a link was made by the dental profession between the occlusal relationships of the teeth and orofacial pain. Early on it was observed clinically that in some patients changes in the occlusal condition seemed to be associated with a reduction in pain. Unfortunately, at that time we had very little understanding or appreciation for the scientific method that could be used to better define this association. Instead, we made some assumptions regarding connections between what we knew (occlusion) and what we really did not know well (the pathophysiology of pain). Our early mentors taught by authority and not necessarily by reason or evidence. This seemed to fit nicely with the mechanistic model that we dentists understood and used in managing most of our patients' common dental problems. However, it eventually became obvious that there were significant inconsistencies in achieving success with our orofacial pain patients. We then began to ask more questions that would help us better understand these patients' problems.

By the late 1980s, the profession began to appreciate and embrace the concept of basing our treatment decisions on scientific studies and not just assuming that our mentors were correct. This stirred up much controversy, not only because it discredited some mentors but also because it forced us to give up concepts that we had accepted that had no scientific merit. We learned, as we have continued to learn, that it is difficult to change belief models.

By the late 1990s, the scientific method became more embraced by the profession and we began to hear the term *evidence-based medicine*. Significant research funding became available, especially for the investigation of pain. However, much of this research was in the basic science domain, leaving the clinician with little connection to the findings. Realizing the need to link these research findings to the practice of medicine and dentistry, the concept of "translational science"

became a standard goal. Translational science is exactly what this text offers. It presents a state-of-the-art description of the known biology of TMDs and orofacial pain, as well as of developing concepts, in a format that can be translated into the clinical management of patients.

Another important feature that was uncovered by basic science research was that pain is pain. Although there are definitely some unique features of the masticatory structures, we have learned that the mechanism by which nociceptive impulses are initiated, transmitted, and perceived as pain is not unique to the masticatory system but in fact common to all other areas of the body. We have also learned to appreciate that dentistry and medicine blend together in the area of orofacial pain. The mechanistic model first embraced by the dental profession can no longer explain the pain our patients experience, especially as it becomes chronic. In fact, most chronic orofacial pain conditions are very similar to other chronic pain conditions managed in the medical field. Moreover, many of the chronic pain patients have two or more pain conditions simultaneously. The evidence-based research in orofacial pain has moved us away from teeth to the vast field of understanding human pain and suffering.

Although we have advanced greatly in the field of TMDs and orofacial pain, our knowledge is still incomplete. Yet every day clinicians meet patients who ask for help with their pain and suffering. We must take the best scientific evidence available and determine the most appropriate treatment for each patient. This is not always an easy undertaking, yet it is the most critical task that needs to be accomplished for the patient. This is the concept behind "best practice." This text will help clinicians make many of these very important decisions for their patients. The most essential factor to consider is to always select the most conservative approach and to do no harm. The human being is a remarkably complex organism with a great ability to adapt and recover. The most conservative approach to therapy is often adequate to enhance this recovery.

I commend Drs Greene and Laskin for their efforts in assembling this fine text. I also applaud the contributing authors, many of whom have dedicated their life's work toward gaining a better understanding of why and how our patients suffer and what can be done to help them. The true value of this book will be measured not only by the number of clinicians who read it but also by how they use this information to reduce the pain and suffering of their patients. This is the ultimate responsibility of the health care provider.

Jeffrey P. Okeson, DMD

Professor and Chair, Department of Oral Health Science
Provost's Distinguished Service Professor
Director, Orofacial Pain Program
College of Dentistry, University of Kentucky
Lexington, Kentucky

The central theme of this book arises from a single question: What is happening in basic and clinical research today that likely will significantly impact the diagnosis and treatment of temporomandibular disorders (TMDs) in the near future? Clearly, the answer to this question must extend far beyond the traditional pain issues that have been the predominant focus of most recent research. The combination of new research tools with innovative experimental designs has produced a large body of information about musculoskeletal disorders, and much of this can be directly or indirectly applied to the temporomandibular joint (TMJ). However, many dental clinicians are unaware of this type of information because it is presented mainly in medical publications or nonclinical scientific journals. Thus, there is a significant information gap between many of the latest advances in the general field of musculoskeletal disease and their potential applications in the clinical management of patients with various TMDs. This is especially true in regard to the issues of acute versus chronic pain. It is the purpose of this book to help bridge this gap.

The book is divided into five sections, each containing numerous chapters that deal with varying aspects of the anatomy, biochemistry, neurophysiology, and psychology of the common TMDs. Chapters dealing with topics such as the biomechanics of normal and abnormal TMJ function, the complexities of TMJ and masticatory myofascial pain, diagnostic technology and markers of disease, pharmacologic management of TMDs, and tissue engineering of joint components provide a strong foundation for discussing other im-

portant issues. Each chapter discusses present knowledge in the particular field and how it may apply to the diagnosis and treatment of TMD patients. In addition, every chapter provides an overview of current new research in the field and its potential for changing future patient care. Included are such clinically relevant topics as the relation of abnormal joint function to joint pathology, the prediction of treatment responsiveness, how sleep disorders affect facial pain, and the role of comorbid conditions in pain response and management. Several chapters also deal with the evolving field of pharmacotherapeutics, including new analgesic drugs, drugs for managing neuropathic pain, and potential drugs for stopping or reversing degenerative joint disease. Because of the numerous technical terms used in this book, an appendix of abbreviations has been added.

We are fortunate to have as contributors to this book a group of international authors who are recognized as leading experts in their fields and who have contributed significantly to our current knowledge through their well-known research and publications. We wish to thank them for their time and effort in accepting the challenge of writing chapters with a focus on future clinical applications of their knowledge. Ultimately, we hope that the information they have offered in this book will provide the reader with a better understanding of the complexities of the various TMDs, which should help to make their management easier and more successful now as well as in the future.

contributors

Rafael Benoliel, BDS (Hons), LDS, RCS (Eng)

Professor
Department of Oral Medicine
Faculty of Dentistry
Hebrew University Hadassah
Jerusalem, Israel

Maria C. Carra, DDS, PhD

Postdoctoral Researcher
School of Dentistry
University of Parma
Parma, Italy

Di Chen, PhD

Professor and Chair
Department of Biochemistry
Rush University
Chicago, Illinois

Robert E. Delcanho, BDS, MSc

Clinical Associate Professor
Faculty of Medicine and Dentistry
University of Western Australia
Perth, Australia

Thomas G. H. Diekwisch, DDS, PhD(sc), PhD(phil)

Professor and Head
Allan G. Brodie Endowed Chair
Department of Oral Biology
College of Dentistry
University of Illinois
Chicago, Illinois

Ronald Dubner, DDS, PhD

Professor
Department of Neural and Pain Sciences
University of Maryland Dental School
Baltimore, Maryland

Eli Eliav, DMD, MSc, PhD

Professor and Chair
Department of Diagnostic Sciences
Director, Center for Temporomandibular Disorders
and Orofacial Pain
Susan and Robert Carmel Endowed Chair in Algesiology
New Jersey Dental School
University of Medicine and Dentistry of New Jersey
Newark, New Jersey

Rüdiger Emshoff, Univ-Doz, Dr med Dr (H)

Associate Professor
University Clinic of Oral and Maxillofacial Surgery
Innsbruck Medical University
Innsbruck, Austria

James Friction, DDS, MS

Professor
School of Dentistry
University of Minnesota
Minneapolis, Minnesota

Senior Research Investigator
HealthPartners Research Foundation
Bloomington, Minnesota

Luigi M. Gallo, Dr sc techn

Professor
Clinic of Masticatory Disorders, Removable Prosthodontics,
Geriatric and Special Care Dentistry
Center of Dental Medicine
University of Zurich
Zurich, Switzerland

Geoffrey E. Gerstner, DDS, MS, PhD

Associate Professor
Department of Biologic and Materials Sciences
School of Dentistry
Department of Psychology
College of Literature, Sciences and the Arts
University of Michigan
Ann Arbor, Michigan

Charles S. Greene, DDS

Clinical Professor
Department of Orthodontics
College of Dentistry
University of Illinois
Chicago, Illinois

David C. Hatcher, DDS, MSc, MRCD(C)

Adjunct Professor
Department of Orthodontics
School of Dentistry
University of the Pacific

Clinical Professor
Department of Orofacial Sciences
School of Dentistry
University of California at San Francisco
San Francisco, California

Private practice
Diagnostic Digital Imaging
Sacramento, California

Jing Hu, DDS, PhD

Professor and Chair
Center of Orthognathic and TMJ Surgery
Department of Oral and Maxillofacial Surgery
West China School of Stomatology
Sichuan University
Chengdu, Sichuan, China

Eric Ichesco, BS

Research Laboratory Specialist
Department of Biologic and Materials Sciences
School of Dentistry
Chronic Pain and Fatigue Research Center
School of Medicine
University of Michigan
Ann Arbor, Michigan

Jan Harm Koolstra, PhD

Associate Professor (Dr)
Department of Oral Cell Biology and Functional Anatomy
Academic Centre for Dentistry Amsterdam
Amsterdam, The Netherlands

Regina Landesberg, DMD, PhD

Associate Professor
Division of Oral and Maxillofacial Surgery
School of Dental Medicine
University of Connecticut
Farmington, Connecticut

Daniel M. Laskin, DDS, MS

Professor and Chairman Emeritus
Department of Oral and Maxillofacial Surgery
Schools of Dentistry and Medicine
Virginia Commonwealth University
Richmond, Virginia

Stefan Lauer, MD

Research Fellow
Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Perth, Australia

Gilles J. Lavigne, DMD, MSc, PhD, FRCD(C)

Professor of Oral Medicine
Canada Research Chair in Pain, Sleep and Trauma
Dean, Faculty of Dental Medicine
University of Montreal

Sleep and Biological Rhythm Center
Montreal Sacré-Coeur Hospital
Montreal, Quebec, Canada

Thomas List, DDS, Odont Dr

Professor and Chair
Department of Stomatognathic Physiology
Faculty of Odontology
Malmö University
Malmö, Sweden

Guido M. Macaluso, MD, DDS, MDS

Professor of Clinical Dentistry
School of Dentistry
University of Parma
Parma, Italy

Dorrit W. Nitzan, DMD

Professor
Department of Oral and Maxillofacial Surgery
School of Dental Medicine
Hebrew University Hadassah
Jerusalem, Israel

Richard Ohrbach, DDS, PhD

Associate Professor
Department of Oral Diagnostic Sciences
Buffalo School of Dental Medicine
University at Buffalo
Buffalo, New York

Sandro Palla, Dr med dent

Professor Emeritus
Clinic of Masticatory Disorders, Removable Prosthodontics,
Geriatric and Special Care Dentistry
Center of Dental Medicine
University of Zurich
Zurich, Switzerland

David A. Reed, PhD

Postdoctoral Fellow
Department of Oral Biology
College of Dentistry
University of Illinois
Chicago, Illinois

Ke Ren, MD, PhD

Professor
Department of Neural and Pain Sciences
University of Maryland Dental School
Baltimore, Maryland

Callum F. Ross, PhD

Associate Professor
Department of Organismal Biology
University of Chicago
Chicago, Illinois

Robert P. Scapino, DDS, PhD

Professor Emeritus
Department of Oral Biology
College of Dentistry
University of Illinois
Chicago, Illinois

Tobias Schmidt-Wilcke, MD, MA

Associate Professor
Department of Neurology
University of Tübingen
Tübingen, Germany

Stephan A. Schug, MD

Professor and Chair
Pharmacology, Pharmacy and
Anaesthesiology Unit
School of Medicine and Pharmacology
University of Western Australia

Director of Pain Medicine
Royal Perth Hospital
Perth, Australia

Petra Schweinhardt, MD, PhD

Assistant Professor
Faculty of Dentistry
McGill University
Montreal, Quebec, Canada

Barry J. Sessle, MDS, PhD, DSc(hc), FRSC, FCAHS

Professor and Canada Research Chair
Faculty of Dentistry
University of Toronto
Toronto, Ontario, Canada

Christian S. Stohler, DDS, Dr Med Dent

Professor and Dean
School of Dentistry
University of Maryland
Baltimore, Maryland

Adjunct Professor
School of Dentistry
University of Michigan
Ann Arbor, Michigan

Peter Svensson, DDS, PhD, Dr Odont

Professor
Section of Clinical Oral Physiology
Department of Dentistry
Aarhus University
Aarhus, Denmark

Ana Velly, DDS, MS, PhD

Assistant Professor
Faculty of Dentistry
Centre for Clinical Epidemiology and Community Studies
Jewish General Hospital
McGill University
Montreal, Quebec, Canada

Sunil Wadhwa, DDS, PhD

Associate Professor
Director, Division of Orthodontics
College of Dental Medicine
Columbia University
New York, New York

Yehuda Zadik, DMD, MHA

Chief Dental Officer
Israeli Air Force Surgeon General Headquarters
Israel Defense Forces, Tel Hashomer

Department of Oral Medicine
Oral and Maxillofacial Center, Medical Corps
School of Dental Medicine
Hebrew University Hadassah
Jerusalem, Israel

Songsong Zhu, DDS, PhD

Associate Professor and Vice-Chair
Center of Orthognathic and TMJ Surgery
Department of Oral and Maxillofacial Surgery
West China School of Stomatology
Sichuan University
Chengdu, Sichuan, China

Understanding Regional and Widespread Pain Phenomena

The five chapters in this section are devoted to topics that expand the understanding of orofacial and temporomandibular disorder (TMD) pain phenomenology. The authors have summarized the current research in their respective areas, and they offer projections for future applications of that research to the clinical situation. Advances in these areas are having a profound impact on both researchers and clinicians, and already many of those advances are being applied to the management of TMD patients.

In the Dubner, Ren, and Sessle chapter, the newest concepts of pain neurophysiology are well summarized in just one of their sentences: “An emerging concept is that the immune cells, glia, and neurons form an integrated network in which activation of an immune response modulates excitability of pain pathways.” This is one of many fresh insights that their chapter provides regarding pain mechanisms in general and specifically musculoskeletal pain.

Benoliel, Svensson, and Eliav have reviewed the extensive literature on muscle pain, with special emphasis on masticatory myofascial pain. This review shows that many factors may be involved in the etiology and pathophysiology of such pain, including host susceptibility, genetically influenced physical traits, psychologic issues, and environmental parameters such as ethnicity, culture, and stress. Thus, this type of pain appears to be more complex than joint pain, which leads them to conclude that in the future “emerging pharmacotherapeutic targets [will] appear at various levels, including receptors, regulatory proteins, and downstream enzymes.”

Emshoff brings his wide experience in the study of temporomandibular joint arthritis to his extensive review of the

literature on that topic. Many of the etiopathologic features of osteoarthritis in general have been elucidated in recent years, and this has shown that detrimental changes in bone, cartilage, and synovium appear to be interconnected in the pathogenesis of this disease. These findings have led him to conclude that future therapeutic areas on which to focus should include osteochondral angiogenesis, mitochondrial dysfunction, and chondroprotection through lubrication.

The topic of comorbidity has only recently become well recognized and widely studied in the pain field. The various conditions that are found to coexist in many TMD patients (especially chronic TMD patients) not only complicate the diagnosis of their facial pain complaints but also clearly affect the management of these problems. As Velly, Schweinhardt, and Fricton point out, clinicians need to identify comorbid conditions in TMD patients early so as to provide proper therapy to manage their TMD pain. This may require collaboration with other health care providers as part of a comprehensive rehabilitation treatment program. Their chapter provides the latest information on this important topic, along with suggestions for managing such patients clinically.

Macaluso, Carra, and Lavigne have provided an overview of how the topics of sleep and pain have converged in recent years. Sleep studies of pain and non-pain patients have demonstrated important differences between them. This has led to the conclusion that sleep deprivation and fragmentation have an essential role in the way pain is perceived and exacerbated. Sleep problems can exacerbate pain, and intense pain or variable pain intensity can lead to poor sleep. All concerned clinicians must be prepared to deal with this reality.

Sensory Mechanisms of Orofacial Pain

Ronald Dubner, DDS, PhD

Ke Ren, MD, PhD

Barry J. Sessle, MDS, PhD, DSc(hc), FRSC, FCAHS

This chapter reviews the processes involved in orofacial sensory functions and their clinical correlates. Particular emphasis is given to temporomandibular joint (TMJ) and masticatory muscle pain and their underlying mechanisms.

Peripheral Mechanisms

The TMJ and masticatory muscles are innervated by the primary afferent (sensory) nerve fibers of the trigeminal nerve. These fibers terminate as sense organs (receptors) that respond to peripheral stimulation of the tissues.¹⁻³ The large-diameter, fast-conducting primary afferent nerve fibers (namely, the A-alpha [$A\alpha$] and A-beta [$A\beta$] afferents) end in the tissues, typically with connective tissue or epithelial cell specializations encapsulating their endings. These receptors respond to low-threshold (non-noxious) mechanical stimuli or movements. In primate jaw-closing and lingual muscles, some of these large-diameter afferent endings are associated with muscle spindles and Golgi tendon organs that respond, respectively, to muscle stretch and contractile tension; other orofacial muscles have few, if any, of these specialized endings. Some of the small-diameter, slow-conducting primary afferents (A-delta [$A\delta$]; C) instead terminate principally as free nerve endings, some of which can respond to non-noxious thermal stimuli (ie, warm or cold thermoreceptors). However, most free nerve endings are activated by noxious stimuli and are therefore termed *nociceptors*.

Activation of the nociceptive endings in the TMJ and masticatory muscles can ultimately lead to the perceptual, reflex,

and other behavioral responses characterizing musculoskeletal pain. In contrast, the various low-threshold receptors in these tissues and their afferent inputs to the central nervous system (CNS) play a role in responses evoked by stimuli related to non-noxious joint position, movement, and muscle stretch or tension.^{4,5} It has been known for several decades that the TMJ is supplied by afferents principally in the auriculotemporal branch of the mandibular nerve and that in most mammalian species the richest innervation is in the posterolateral aspect of the TMJ capsule. However, there is conflicting data on whether the articular surfaces and disc of the TMJ are innervated. The innervating fibers may not all be sensory (ie, afferents) but may include efferents of the sympathetic nervous system.^{1-3,6} Free nerve endings are abundant in the TMJ and also in the masticatory muscle tissues, but more specialized receptors are sparse except for those muscles with muscle spindles and Golgi tendon organs.


About 40 years ago, the first electrophysiologic investigations were made of the response properties of TMJ and masticatory muscle afferents.^{1,6-8} They documented that low-threshold non-nociceptive afferents have either slowly adapting or rapidly adapting responses to jaw movement or change in condylar position, and these responses were implicated in the sense of jaw movement and jaw position sense (kinesthesia). It became apparent, however, that other primary affer-

Table 2-1 Diagnostic criteria for masticatory myofascial pain	
Myofascial pain*	Myofascial pain with or without limited opening†
Regional, dull, aching pain <ul style="list-style-type: none"> • Aggravated by mandibular function 	Axis I: Physical findings Complaint of pain of muscle origin <ul style="list-style-type: none"> • In jaw, temples, face, preauricular, or auricular at rest or during function
Hyperirritable sites or trigger points <ul style="list-style-type: none"> • Frequently found within a taut band of muscle tissue or fascia • Provocation of these trigger points alters the pain complaint and reveals a pattern of referral • More than 50% reduction of pain is inducible by muscle stretch preceded by trigger point treatment with vapocoolant spray or local anesthetic injection Signs and symptoms that may accompany pain <ul style="list-style-type: none"> • Sensation of muscle stiffness • Sensation of acute malocclusion, not clinically verified • Ear symptoms, tinnitus, vertigo, toothache, tension-type headache • Decreased mouth opening; passive stretching increases opening by > 4 mm • Hyperalgesia in the region of referred pain 	Pain associated with localized areas of tenderness to palpation in muscle Pain on palpation in more than three of the following sites and at least one of which is ipsilateral to the pain complaint (right/left [R/L] muscles count for separate sites): <ul style="list-style-type: none"> • R/L temporalis: posterior, middle, anterior, tendon (8 sites) • R/L masseter: origin, body, insertion (6 sites) • R/L posterior mandibular region (2 sites) • R/L submandibular region (2 sites) • R/L lateral pterygoid region (2 sites) Myofascial pain as above accompanied by: <ul style="list-style-type: none"> • Stiffness of muscles • Pain-free unassisted mandibular opening of > 40 mm • With assistance, an increase of ≥ 5 mm in mandibular opening
No psychosocial assessment required	Axis II: Psychosocial comorbidity‡ Pain intensity and pain-related disability <ul style="list-style-type: none"> • Graded chronic pain scale • Jaw disability checklist Depression and somatization <ul style="list-style-type: none"> • Symptom checklist for depression and somatization (SCL-90)

*American Academy of Orofacial Pain.²†Research Diagnostic Criteria for Temporomandibular Disorders.³‡Other validated measures may be used.⁴

The early pathophysiological theories offered “one cause, one disease” hypotheses involving such things as muscle hyperactivity, altered occlusion, or stress. However, these theories were largely based on cross-sectional studies that are not adequate for establishing causality or possible risk factors. Accumulated data have now indicated a more complex etiology, and the most current concepts are the multifactorial^{14,15} and biopsychosocial¹⁶ theories. Both of these theories propose a complex interaction between environmental, emotional, behavioral, and physical factors and have increased our understanding of the factors involved at a population or group

level. However, specific risk factors may not be active in any given case, and therefore these concepts still do not explain why an individual patient develops MMP. Dworkin et al^{17,18} approached the question of pathophysiology using prospective studies and showed early on the importance of risk factors such as the psychologic profile and the presence of pain in other sites. These and other studies have established psychosocial distress and impaired pain modulation as the two major emerging factors in understanding the etiology of persistent MMP.^{19–22} It has become clear that these factors act within a milieu of further instigating or modulatory factors such

**Fig 2-1**

A complex disease model of MMP. Overall, it is reasonable to assume that MMP shares many of the features of other persistent pain conditions.²⁴ The pain in MMP occurs within a framework of nervous system changes initiated by external events and modified by various intrinsic factors (eg, mood, cognitive set, neurodegeneration).²⁴ It can also be viewed as a “gene by pain modulatory circuits by environment” interaction.²³ Multiple genes have been identified (eg, COMT, α -adrenoreceptor 2, glucocorticoid receptors, protein kinase, muscarinic receptors, transcription coregulators, and phosphorylators of G proteins^{25–27}) that carry an increased risk for higher pain sensitivity. Environmental factors can increase the risk either through psychosocial mechanisms or physical factors such as trauma. The overall presentation of pain is determined by the interplay of several “brain” factors like context, cognition, mood, learning, memory, sleep, and neurodegeneration that affect inhibitory circuits.^{23,24} Furthermore, biologic sex and ethnicity may influence the balance between factors.^{23,24,28}

as genetics, proinflammatory states, cardiovascular and neuroendocrine function, trauma, and the social and environmental makeup of the individual²³ (Fig 2-1). Baseline data from the Orofacial Pain Prospective Evaluation and Risk Assessment (OPPERA) case-control study support the idea that TMDs are complex multifactorial conditions.²⁹ At this stage, the onset cases in the OPPERA study largely (85%) suffer from both MMP and TMJ disorders,^{30,31} limiting the conclusions that can be drawn specifically about MMP pathophysiology.

Nervous System Alterations in MMP Patients

Pain modulation and MMP

Complex behavioral influences such as anxiety, depression, belief states, and cognition can separately influence pain perception and the pain experience. A key system that is able to




Fig 3-5 Hypothetical model of cartilage and subchondral bone interaction in OA. (a) Healthy chondrocytes suffering from a pathologic strain (due to instability of the joint or severely increased mobilization) start to become hypertrophic and produce growth factors (eg, VEGF) that diffuse toward the underlying bone marrow and stimulate osteoclastogenesis. (b) Persisting strain. Chondrocytes become more hypertrophic and produce less sulfated glycosaminoglycans (sGAG) to sustain the cartilage. Osteoclasts start to tunnel through the subchondral bone, inducing the first changes to the biomechanical properties of the tissue. (c) Progressive phase of OA. The tidemark between cartilage and bone shifts upward, reducing cartilage thickness. The remaining cartilage is strongly depleted of sGAG and becomes structurally deprived. Osteoclast activity extends into the calcified cartilage up to the border with the deep zone of the cartilage. There is vascular ingrowth into the cartilage via the pores. Later on, osteoblasts will infiltrate and start to deposit bone, resulting in end-stage sclerosis. (Reprinted from Weinans et al⁶² with permission.)

and that the activated HIF-1 can induce osteoclastogenesis via repression of osteoprotegerin expression.

Subchondral bone

An intriguing aspect of OA is the increased turnover and subsequent changes in the subchondral bone. One of the few known molecules that could initiate this high turnover is VEGF. It has been observed that the deep articular chondrocytes show VEGF expression 2 weeks after OA induction by anterior cruciate ligament transection (ACLT) or a combination of ACLT and partial meniscectomy in the rat.⁶⁵ In vitro studies have shown that chondrocytes respond to mechanical overloading with the expression of HIF-1 α and VEGF, subsequently leading to the induction of MMP-1, -3, and -13, which mediate a cartilage-destructive process.^{61,66} VEGF has also been shown to promote angiogenesis and osteoclastogenesis as a

consequence of overloading, which could potentially initiate a cascade leading to subchondral plate resorption and high subchondral bone turnover⁶⁷ (Fig 3-5).

An interesting molecule in this respect is sclerostin,⁶⁸ which was found to have greater expression in the chondrocytes in OA joints than in the chondrocytes in healthy joints.⁶⁹ Sclerostin inhibits the wingless/integrated (Wnt) signaling pathway, and Wnt signaling is known to be critically involved in the biology of the cartilage–subchondral bone unit.⁷⁰ An attempt to avoid an OA-related phenotype upregulation of sclerostin by chondrocytes could be the rescue response. In this way, cartilage degradation could be prevented while bone remodeling would be stimulated. This hypothesis has been supported by study findings in a rat model in which Wnt signaling inhibition indeed protected against the progression of OA.⁷¹




Fig 9-6 Box-and-whisker plots of the work done to the disc (in mJ) during different jaw movements (median, 25th, and 75th percentiles).




Fig 9-7 Mechanical work done to the disc (in mJ) for each TMJ during different jaw movements. Each number on the abscissa represents a TMJ. Notice that all movements lead to significantly larger mechanical work in numbers 8, 9, and 14 than in the others. A—open-close 1.0 Hz; B—open-close 0.5 Hz; C—protrusion; D—laterotrusion ipsilateral TMJ; E—laterotrusion contralateral TMJ.

Stress-Field Translation and Condyle Metabolism


Mechanical loading during movement is essential for maintenance of the articular tissues because, by regulating tissue remodeling, mechanical forces maintain healthy cartilage. However, not all loading conditions have a positive effect on cartilage metabolism. For instance, while cyclic loading or loading within a physiologic range increases proteoglycan synthesis, cartilage overloading, underloading, and static loading cause proteoglycan depletion.⁶² Mechanical loading leads to compression of the articular cartilage and matrix deformation, stimulating the chondrocytes' metabolic activity. In particular, the mechanical loading leads to complex changes within the tissue that include matrix and cell deformation, hydrostatic pressure gradients, fluid flow, altered matrix water content and changes in osmotic pressure, and ion concentration. Chondrocyte mechanoreceptors such as mechanosensitive ion channels and integrins are involved in recognition of these mostly physical changes (mechanotransduction). For instance, activation of the mechanosensitive ion channels by the mechanical stimulation leads to ion influx, in particular calcium ions, and activates intracellular signaling pathways that modulate protein synthesis (see Ragan et al¹⁰ for detailed information).

Chondrocytes respond to mechanical stimuli by activating anabolic or catabolic pathways. Changes from anabolic to catabolic signaling can lead to DJD. Consequently, cell-matrix interactions are essential for maintaining the integrity of the articular cartilage, and an intact matrix is essential for chondrocyte survival and transmission of mechanical signals.

The authors' pilot experiments showed that plowing can compromise cartilage integrity in a force-related manner by causing cell death at the cartilage surface. In addition, plowing alters chondrocyte metabolism by increasing the expression of the catabolic enzyme stromelysin-1 (matrix metalloproteinase 3 [MMP-3]), slightly decreasing that of aggrecan, and augmenting the degree of glycosaminoglycan (GAG) degradation (Figs 9-8 and 9-9). Plowing caused an increase in catabolic activities starting with a compression force of 25N and a decrease of the anabolic activity starting between 50 and 100 N. These results should be interpreted with caution and without inferring that this loading regimen definitely initiates a degenerative process, because the altered metabolism could simply represent remodeling activity.

Cartilage has a poor intrinsic healing capacity.⁶⁴ Nevertheless, after injury, the healthy chondrocytes promote a remodeling process involving the elimination of the damaged matrix and the building of new extracellular matrix (ECM). It is therefore possible that in the plowed cartilage the viable chondrocytes start remodeling the matrix by producing

Fig 11-1 (a) Illustration of a normal TMJ. (b to d) Pressure in the TMJ upon tooth clenching (b) and the resulting stuck disc (c and d). When the pressure on the disc ceases, its central area is separated from the bony surface, creating a vacuum that causes the periphery of the disc to adhere firmly to the surface of the eminence, thus preventing it from sliding (red arrow). At this point, an attempt to open the mouth causes pain as the condyle is pulled forward, away from the adhered disc (stars indicate pain locations). (e) The disc is not released on the introduction of a needle. (f) The disc is released following lavage of the upper compartment of the joint. Adhesive forces, rather than only the vacuum effect, are responsible for the immobilization.



has been shown that degradation of HA by hyaluronidase does not detrimentally affect joint lubrication.³⁰ Interestingly, there is no significant difference in the molecular size of HA in the synovial fluid of patients with disc displacement and healthy individuals.³¹ Thus, it was realized that HA is not a lubricant per se and that adding high-molecular weight HA to the synovial fluid does not affect the friction coefficient. However, a significant increase in the coefficient of friction was observed after the HA in the synovial fluid was changed to low-molecular weight HA,³² thus supporting the possibility that HA has an indirect effect on joint lubrication. Hence, an array of other possible functions of HA in joint movement has been proposed, among which were the roles of a space filler, a wetting agent, a flow barrier within the synovium, and a protector of the cartilage surfaces.^{33,34} Besides its mechanical role in joint function, HA has been found in vitro to support joint integrity biochemically by acting as a protector against the action of phospholipase, an inhibitor of phagocytosis and chemotaxis, and as an anti-inflammatory agent. It also prevents the formation of scar tissue and angiogenesis.³³

According to Swann et al,³⁵ the main synovial lubricant is a large water-soluble proteoglycan, which they termed *lubricin* and which is also known as *superficial zone protein* and *proteoglycan 4*. The multifaceted lubricin, which is encoded by the PRG4 gene, has a molecular weight of 206 kDa and consists of approximately equal proportions of protein and glycosaminoglycans.³⁶ The latter contain negatively charged sugars, which possibly create the strong repulsive hydration forces that enable the molecule to act as a boundary lubricant. It is synthesized and selectively secreted by superficial chondrocytes in the articular cartilage (hence the term *superficial zone protein*) and by synovial lining fibroblast-like cells. The lubricin in the synovial fluid reduces the coefficient of friction of the articular cartilage surfaces,³⁷ and accordingly it prevents cartilage wear and synovial cell adhesion and proliferation. Several studies also imply that lubricin expression plays a role in condylar cartilage growth.³⁶

It has been proposed that lubricin expression is regulated by mechanical stress; however, its influence regarding the TMJ remains unclear. Exposing synoviocytes, chondrocytes,

Page numbers with “f” denote figures; those with “t” denote tables; those with “b” denote boxes.

1,2-dimyristoyl-sn-glycero-3-phosphocholine, 128

5-hydroxytryptophan, 4

A

A-alpha fibers, 3

A-beta fibers, 3

Acute orofacial pain, 83–84, 92

ADAMTS4, 158–159

Adaptation, 120

A-delta fibers, 3–4, 6

Adenosine 5-triphosphate, 4

Adenosine monophosphate-activated protein kinase, 42

Adenoviral vector expressing human insulinlike growth factor-1, 179

Advanced glycation end products, 161

Aggrecanases, 34, 159, 180

Allodynia, 6, 15, 21

$\alpha 2\delta$ modulators, 188–189

alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate, 9

Amygdala, 151

Anabolic signaling, 107

Anchored disc phenomenon, 127

Angiogenesis

 factors that affect, 157

 osteocondral, 42

Animal models

 biomarkers developed using, 159–161

 of osteoarthritis, 41

Anterior cingulate cortex, 13, 147f, 148

Anterior insula, 149

Antidepressants, 53, 186–187, 189

Arterial spin labeling, 143

Arthrocentesis, 127–129

Arthrography, 135

Articular bone, 172

Articular cartilage

 autophagy in, 42

 avascular properties of, 42, 116

 collagenous fibers of, 116

 deforming properties of, 113, 116

 evolution of, 172

 metabolism of, 177

 in osteoarthritis, 34–39, 37f

 principal stress in, 115, 117f

Articular disc

 anteriorly displaced, 118

 description of, 99, 101

 energy density vs internal strain energy, 106

 finite element analysis of, 114

 friction effects on, 118

 internal derangement effects on, 119

 joint lubrication functions of, 102

 lubricating system of, 124

 mechanical behavior of, 118–119

 plowing force of, 104

Astrocytes, 13

Autonomic nervous system, 20

Autophagy, 42

B

Back pain, 51

Benzodiazepines, 186–187

Biglycan, 160

Bilateral sagittal split osteotomies, 84

Biomarkers

 aggrecanases, 159

 animal models used to develop, 159–161

 collagenases, 158–159

 C-terminal telopeptide-II, 159

 interleukin-1 β , 156–157

 monocyte chemoattractant protein, 157

 prostaglandins, 157

 of temporomandibular joint-osteoarthritis, 159–161

 tumor necrosis factor- α , 156–157

Biomechanical modeling, 137–138, 138f, 140

Biomedical engineering, 138–140

Blood oxygen level-dependent imaging, 142

Bone morphogenetic proteins

 BMP-2, 167, 179

 description of, 40

Boundary lubrication, 124

Bradykinins, 4

Brain-derived neurotrophic factor, 4

Brain-imaging studies, 13

Brainstem nociceptive processing, 6, 8

Bruxism

 description of, 24, 62

 sleep, 61–62

C

Calcitonin gene-related peptide, 6

Candidate gene studies, 72

Cannabinoids, 190–191

Cartilage. *See* Articular cartilage.

Catabolic signaling, 107

Catastrophizing, 52, 95

Catechol-O-methyltransferase, 20, 25–26, 71, 87

Central sensitization, 8–12, 14–15, 141, 188, 190

Cerebral blood flow, 13

C-fibers, 4, 6

Chairside screening, 86

Chemical condylectomy, 128

Chemokines, 157

- Chondrocyte(s)
 anabolic and catabolic factors that regulate, 38f
 description of, 34, 36f, 38f
 hypertrophic-like changes, 36f, 40f
 mechanical stimuli effects on, 107
 osteoarthritic, 102
 sclerostin expression in, 39
 vascular endothelial growth factor induction in, 38
- Chondrocyte receptors, 38
- Chondroitin sulfate, 159
- Chronic pain
 acute pain progression to, 92
 description of, 151
 factors involved in, 50f
 glutamate and, 191
 masticatory myofascial pain and, 95
 prefrontal cortex involvement in, 13
 risk model for, 96
 sleep disorders and, 57, 60–62
- Cinderella hypothesis, 24
- Cingulate cortex, 147f, 148–149
- Cingulotomy, 148
- Cluster headaches, 26
- Clustering, 96–97
- Cognitive-behavioral therapies, 53, 63, 94–95, 97
- Collagenases, 34
- Collagenous fibers, 116
- Community genomics, 74
- Comorbid pain conditions
 description of, 1
 evidence-based treatment for, 53
 factors that affect, 52
 fibromyalgia, 20–21, 26, 49–50
 headache, 50, 62–63
 implication of, 51t
 masticatory myofascial pain, 26
 migraine headache, 50
 neck pain, 51
 self-management programs for, 53
 sleep disturbances caused by, 61
 studies of, 48t–49t
 summary of, 53
 treatment of, 52–53
 treatment responsiveness affected by, 95
- Complete Freund's adjuvant, 9
- Complex diseases
 characteristics of, 92
 definition of, 92
 description of, 72–73
 immune system's role in, 73, 73f
 phenotype, 75–76
- Computer-aided design/computer-aided manufacturing technology, 139
- Conditioned pain modulation, 83, 83f
- Condition-specific measures, 93
- Condylar blastema, 172
- Condyle-fossa distance, 103f, 104
- Cone beam computed tomography, 131, 134–135, 136f
- Coping, 52
- Corticosteroids, 128, 186
- COX-1, 157
- COX-2, 157
- Craniofacial deformities, 137
- C-terminal telopeptide-II, 159
- Cytokines
 description of, 126
 interleukin-1 β , 156–157
 monocyte chemoattractant protein, 157
 prostaglandins, 157
 tumor necrosis factor- α , 156–157
- D**
- Deep bite, 23
- Deep sequencing, 77
- Deep sleep, 58
- Degenerative joint disease. *See* Osteoarthritis.
- Depression, 22, 93, 95
- Descending modulation, 10–12, 11f
- Diagnostic imaging, 133–137
- Diffuse noxious inhibitory controls, 10, 83–84, 86
- Diffusion tensor imaging, 142
- Dimethyl sulfoxide, 186
- Disc displacement, 109, 123, 136f
- Discoidin domain receptor 2, 160
- Disease
 complex. *See* Complex diseases.
 preclinical symptoms of, 92
- Dorsolateral prefrontal cortex, 12
- Dynamic brain imaging, 131
- Dynamic loading, 102
- Dynamic stereometry, 103, 109–110
- E**
- Education-based self care model, 94
- Effective connectivity magnetic resonance imaging, 142
- Endochondral ossification, 40–41, 172
- Endophenotypes, 76
- Energy density, 106
- Enkephalin, 10
- Enzymes, degradative, 158–159
- Epigenetics, 69, 73–74
- Epigenome, 74
- Epigenomics, 74
- Ethnicity, 21–22
- Etiology, 91–92
- Evidence-based treatment, 53
- Extracellular matrix, 34–35, 41, 107

F

- Fibromodulin, 160
- Fibromyalgia, 20–21, 26, 49–50
- Fibrous mesenchyme, 169
- Finite element analysis
 - applications of, 99, 115–119
 - challenges for, 120
 - description of, 113
 - future of, 119–120
 - history of, 114–115
 - purposes of, 114
 - safety applications of, 119
 - stress and strain values, 115–116
 - surgical planning uses of, 119
 - temporomandibular disorders application of, 119–120
 - temporomandibular joint applications of
 - adaptation predictions, 120
 - history of, 114–115
 - mechanical behavior, 118–119
 - normal function, 115–116
 - pathologic function, 118
- Friction
 - articular disc affected by, 118
 - inadequate lubrication as cause of, 127
- Functional brain imaging, 77
- Functional connectivity magnetic resonance imaging, 142
- Functional magnetic resonance imaging, 142

G

- Gabapentin, 4, 188–189, 191
- Gene expression, 73–74
- Gene variants, 71f
- Gene-environment interactions, 69, 72, 75, 77
- Gene-gene interactions, 69, 72, 75, 77
- Generic treatments, 96
- Genes, in complex diseases, 72
- Genetics
 - costs of, 70
 - literature regarding, 14
 - masticatory myofascial pain and, 25–26
 - overview of, 69–70
 - single nucleotide polymorphisms, 69
- Genome-wide association studies, 70–71, 77
- Genomic technology
 - advances in, 70–72
 - genome-wide association studies, 70–71, 77
 - single nucleotide polymorphisms, 70–71
- Glia, 13
- Glial cells, 191
- Glutamate, 150, 191
- Glutamate receptors, 21
- Glutamate transporter, 13
- Glycosaminoglycan, 107, 108f, 125

- Gray matter volume, 146–148
- Growth factors, 41

H

- Hard tissue imaging, 133–135, 134f
- Headaches
 - in children, 63
 - migraine, 50, 63
 - sleep bruxism associated with, 62
 - sleep disturbances and, 62–63
 - tension-type, 62–63
- ¹H-MRS. *See* Proton magnetic resonance spectroscopy.
- Host susceptibility, 26
- Human Genome Project, 72
- Human microbiome, 74–75, 75f
- Hyaline cartilage, 118–119
- Hyaluronic acid, 34, 35f, 42, 124–125, 128
- Hyaluronidase, 125
- Hydrostatic lubrication, 124
- Hydrostatic pressure, 115
- Hyperalgesia, 6, 15
- Hypoxia, 25, 157–158
- Hypoxia-inducible factor, 38, 158

I

- Imaging. *See also* Neuroimaging.
 - advances in, 139–140
 - biomechanical modeling after, 137–138, 138f, 140
 - biomedical engineering uses of, 138–140
 - cone beam computed tomography, 131, 134–135, 136f
 - diagnostic, 133–137
 - hard tissue, 133–135, 134f
 - magnetic resonance imaging. *See* Magnetic resonance imaging.
 - of pain, 13
 - soft tissue, 135–137
- IMMPACT. *See* Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials.
- Immune system, 73, 73f
- Incident-cohort studies, 91
- Inferior parietal lobule, 147f
- Inflammatory mediators
 - description of, 4, 155
 - interleukin-1 β , 156–157
 - tumor necrosis factor- α , 156–157
- Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, 93
- Insomnia, 61, 63
- Insula, 149–150
- Insular cortex, 149–150
- Insulinlike growth factor-1, 179–180
- Integrated Pain Adaptation Model, 25
- Interdisciplinary treatment, 52–53
- Interleukin-1 β , 156–157

Interleukin-1 receptor antagonist, 180–181
 Intermediate phenotypes, 76
 Internal derangements, 93, 119
 Internal strain energy, 106
International Classification of Sleep Disorders, 60–61
 Intra-articular injections
 bone morphogenetic protein 2, 179
 corticosteroids, 186
 insulinlike growth factor-1, 179–180
 interleukin-1 receptor antagonist, 180–181
 NEL-like molecule 1, 180
 transforming growth factor beta, 178
 Intraoral appliances, 53, 95

J

Jaw-closing muscles, 113

K

Keratan sulfate, 159

L

Lateral pain system, 146–148
 Lateral pterygoid muscle, 120
 Lifestyle, 25, 27
 Light sleep, 58
 Liposomes, 128
 Low-threshold mechanoreceptive neurons, 6, 8
 Lubrication, of temporomandibular joint, 123–129
 Lubricin, 34, 42, 125–126

M

Macrophage colony-stimulating factor, 41
 Magnetic resonance imaging
 applications of, 136f
 arterial spin labeling, 143
 description of, 135–137
 effective connectivity, 142
 functional, 142
 functional connectivity, 142
 history of, 142
 methods, 142
 operating principles of, 142–143, 143f
 Malocclusions, 23
 Mandibular advancement appliances, 64
 Mandibular condylar cartilage, 173
 Mandibular hypoplasia, 119
 Masticatory myofascial pain
 algorithm of, 19f
 autonomic nervous system and, 20
 characteristics of, 17
 chronic pain and, 95
 comorbidities, 26
 definition of, 47

 diagnostic criteria for, 18t
 ethnicity and, 21–22
 genetic factors, 25–26, 151
 historical perspectives on, 17–19
 host susceptibility to, 26
 lifestyle factors, 25, 27
 nervous system alterations in, 19–21
 neuropeptides and, 20–21, 26
 occlusion and, 23
 pain modulation and, 19–20
 pressure pain thresholds in, 20
 psychosocial factors, 22–23
 sex and, 21
 skeletal morphologic features, 23
 sleep disturbances and, 26–27, 61
 temporomandibular joint disorders and, 23–24
 trauma as cause of, 22
 trigger points associated with, 25
 Matrix metalloproteinases, 34–35, 108f, 158, 180
 Maxillofacial surgery, 119
 Maximal mouth opening, 123–124
 Mechanical loading, 107
 Mechanical temporomandibular disorders, 95–96
 Meckel's cartilage, 168–169, 172
 Medial pain system, 148–150
 Medical care delivery systems, 70
 Mediolateral stress-field translation, 104–105
 Medullary dorsal horn, 6
 Metabolic phenotype, 74
 Metabotropic glutamate receptors, 9
 Metagenomic DNA sequencing, 74
 Methyl salicylate, 186
 Microbiome, 74–75, 75f
 Microglia, 13
 Migraine headache, 50, 63
 Mini-anchors, 119
 Mitochondrial dysfunction, 42
 Modulus, 81
 Monocyte chemoattractant protein, 157
 MRI. *See* Magnetic resonance imaging.
 Muscle hypoperfusion, 25
 Muscle pain
 exogenous models of, 24
 pharmacotherapy for, 53
 Muscle relaxants, 187
 Myalgia, 23–24
 Myofascial pain. *See* Masticatory myofascial pain.

N

N-acetylaspartate, 148, 150
 Neck pain, 22, 51
 NEL-like molecule 1, 180
 Nerve growth factor, 4, 21, 42, 190

- Neuroglial cells, 191
- Neuroimaging. *See also* Imaging.
 antinociceptive areas studied using, 150
 central pain systems studied using, 146–151
 description of, 131, 141
 future applications of, 150–151
 magnetic resonance imaging. *See* Magnetic resonance imaging.
 medial pain systems studied using, 148–150
 positron emission tomography, 144, 144f
 temporomandibular disorder studies, 144, 145t
- Neuropathic pain, 84, 86, 190–191
- Neuropeptides, 20–21, 26
- Neuroplasticity, 92, 190
- Neutrophins, 4
- Next-generation sequencing
 bioinformatics platform for, 72
 description of, 70–72
 whole genome sequencing, 70, 72
- NMDA receptor–ion channel complex, 9f
- NMDA receptors, 21, 191
- Nociception
 non-neural processes in, 12–13
 in sleep, 59
- Nociceptive afferents, 4, 11
- Nociceptive-specific neurons, 6, 8, 10
- Nocturnal migraine headaches, 63
- Non-neural processes, 12–13
- Nonsteroidal anti-inflammatory drugs, 53, 185–186
- Notch1*, 172
- NREM sleep, 58
- N-type calcium channel, 191
- Nuclear factor κ B, 12, 35
- Nucleus raphe magnus, 10
- Numeric rating scales, 81
- O**
- Obstructive sleep apnea, 61
- Occlusal interferences, 23
- Occlusion, 23
- Octahedral shear stress, 115
- Onabotulinum toxin, 186, 188
- Opioid receptors, 10
- Opioids, 10, 187, 189–190
- OPPERA. *See* Orofacial Pain Prospective Evaluation and Risk Assessment.
- Oral appliances, 64
- Orofacial pain
 acute, 83–84
 bruxism secondary to, 62
 central mechanisms of, 6–12
 mandibular advancement appliances for, 64
 peripheral mechanisms of, 3–6, 5f
 21st-century trends, 70
- Orofacial Pain Prospective Evaluation and Risk Assessment, 19, 85, 96
- Orthodontics, 23
- Osteoarthritis
 animal models of, 41
 articular cartilage destruction in, 34–39, 37f, 42
 biologic targets in treatment of, 41–43
 bone changes in, 39–41
 cartilage abnormalities in, 34–39
 characteristics of, 155
 corticosteroids for, 128
 definition of, 33, 101, 131, 177
 etiopathogenic mechanisms of, 34–41, 35f–40f
 features of, 34–41
 friction and, 127
 hyaluronic acid effects in, 42
 inflammatory response in, 41
 lubricin protective effects in, 42
 mitochondrial dysfunction in, 42
 periarticular bone in, 40
 rat meniscectomy model of, 42
 research on, 33–34
 subchondral bone in, 37f, 39f, 39–41
 synovial inflammatory infiltrates in, 41
 synovioathy associated with, 34
 in temporomandibular joint, 101, 109
 treatment of, 41–43, 177
- Osteochondral angiogenesis, 42
- Osteophytes, 41
- Overloading, 127, 127f
- P**
- Pain
 back, 51
 chronic. *See* Chronic pain.
 imaging of, 13
 masticatory myofascial pain. *See* Masticatory myofascial pain.
 neck, 51
 neuropathic, 84, 86, 190–191
 orofacial. *See* Orofacial pain.
 palpation-induced, 93
 persistence of, 51, 96
 progression of, 52f
 provocation, 93
 sleep and, 57, 59–60, 63–64
 temporomandibular disorder–related. *See* Temporomandibular disorder pain.
- Pain adaptation model, 24–25
- Pain modulation, 19–20
- Pain perception
 behavioral conditions that affect, 19
 measurement difficulties for, 72
- Pain-related awakenings, 26

- Pain-related evoked potentials, 149
 - Palpation-induced pain, 93
 - Paradoxical sleep, 58
 - Parafunctional forces, 24
 - Patient-reported outcomes, 93
 - Patient-specific model, 138f
 - Peripheral sensitization, 4–6, 14–15
 - Personalized medicine, 70
 - Pharmacogenomics, 26
 - Pharmacologic treatment
 - $\alpha 2\delta$, 188–189
 - antidepressants, 53, 186–187, 189
 - benzodiazepines, 186–187
 - cannabinoids, 190–191
 - future applications of, 190–191
 - historical review of, 185–186
 - ketamine, 189, 191
 - for muscle pain, 53
 - muscle relaxants, 187
 - nonsteroidal anti-inflammatory drugs, 53, 185–186
 - onabotulinum toxin, 186, 188
 - opioids, 187, 189–190
 - selective serotonin reuptake inhibitors, 187, 189
 - for temporomandibular disorder pain, 185–191
 - Phenotypes
 - functional brain imaging investigations of, 77
 - intermediate, 76
 - Phospholipase, 125
 - Phospholipase A₂, 126
 - Phospholipids, 124, 126, 128–129
 - Placebo effect, 12, 151
 - Plowing force, 102, 102f
 - Polysomnographic recordings, 58, 58b
 - Positron emission tomography, 144, 144f
 - Positron emission tomography/computed tomography, 144
 - Posterior cingulate cortex, 147f, 149
 - Postherpetic neuralgia, 188
 - Preclinical symptoms, 92
 - Prefrontal cortex, 13
 - Pregabalin, 188–189, 191
 - Pressure pain thresholds, 20–21
 - Primary afferent neurons, 5f
 - Primary afferents, 3
 - Primary somatosensory cortex, 147f
 - Principal stress, in articular cartilage, 115, 117f
 - Proinflammatory cytokines, 126
 - PROs. *See* Patient-reported outcomes.
 - Prostaglandin E₂, 20, 157
 - Protein kinase C, 21
 - Proteoglycans, 125, 178
 - Proton magnetic resonance spectroscopy, 142–143
 - Proton pump inhibitors, 188
 - Provocation pain, 93
 - Psychogenic pain, 85
 - Psychologic factors, 52
 - Psychophysics, 79–80
 - Psychosocial factors, 22–23
 - P-type calcium channel, 191
 - Putative etiology, 91–92
- Q**
- Quantitative sensory testing (QST)
 - acute orofacial pain, 83–84
 - afferent nerve fiber functions assessed with, 86
 - applications of, 85–87
 - background of, 79–80
 - conditioned pain modulation, 83, 83f
 - description of, 20
 - diffuse noxious inhibitory controls, 83–84, 86
 - future applications of, 85–87
 - history of, 79–83
 - neuropathic pain, 84, 86
 - response-dependent techniques, 82
 - somatosensory sensitivity, 86–87
 - stimuli used in, 79–80
 - stimulus-detection, 80
 - summary of, 87
 - suprathreshold estimation, 80–83, 81f
 - temporomandibular disorders, 84–85
 - testing algorithms, 80
 - thermal detection thresholds, 84
 - traumatic neuropathic pain, 84, 86
 - triangulation procedure, 81, 82f
- R**
- Receptor activator of nuclear factor κ B, 41
 - Receptor for advanced glycation end products, 35, 161
 - Rehabilitation treatment model, 92, 96
 - REM sleep, 58
 - Research Diagnostic Criteria for TMD, 76
 - Rheumatic diseases, 33
 - Rheumatoid arthritis, 157
 - Rhythmic masticatory muscle activity, 62
 - Risk factors
 - description of, 14
 - genetic, 26
 - Rolling/plowing explants test system, 109
- S**
- Satellite glial cells, 12
 - Scaffold biomaterials, 167
 - Schizophrenia, 74
 - Sclerostin, 39
 - Secondary cartilage, 169
 - Segmental modulation, 10
 - Selective serotonin reuptake inhibitors, 187, 189

- Self care, 96
 - Self-management program, 53
 - Self-report condition-specific measures, 93
 - Serotonin, 20
 - Serotonin noradrenaline reuptake inhibitors, 189
 - Serotonin transporter gene, 25
 - Shear loading, 102
 - Shear stress, 115–116
 - Single nucleotide polymorphisms, 70–71
 - Skeletal morphologic features, 23
 - Sleep
 - average duration of, 57
 - brain activity during, 58
 - deep, 58
 - definition of, 57
 - fragmentation of, 59
 - light, 58
 - medication effects on, 63
 - nociception attenuation during, 59
 - NREM, 58
 - pain and, 57, 59–60, 63–64
 - paradoxical, 58
 - pathophysiology of, 57–58
 - polysomnographic recordings of, 58, 58b
 - REM, 58
 - in sleep bruxism patients, 62
 - Sleep arousals, 58, 61
 - Sleep bruxism, 24, 61–62
 - Sleep deprivation
 - description of, 59
 - migraine headaches precipitated by, 63
 - Sleep disorders/disturbances
 - assessment of, 63, 64b
 - chronic pain and, 57, 60
 - chronic widespread pain and, 61–62
 - classification of, 60t, 60–61
 - comorbid pain conditions as cause of, 61
 - description of, 26–27
 - headaches and, 62–63
 - insomnia, 61, 63
 - masticatory myofascial pain and, 26–27, 61
 - temporomandibular disorders and, 61
 - treatment of, 63
 - Sleep hygiene, 63
 - Sleep-disordered breathing, 61
 - Sleep-related breathing disorders, 61
 - Sleep-related movement disorder, 62
 - SNRIs. *See* Serotonin noradrenaline reuptake inhibitors.
 - Social support, 52
 - Soft tissue imaging, 135–137
 - Somatosensory cortex, 147f, 148
 - Static loading, 102
 - Stimulus-detection thresholds, 80
 - Strain, 115–116
 - Stress
 - disorders related to, 22
 - gene effects during, 76
 - Stress (force)
 - collagenous fiber resistance to, 116
 - finite element analysis of, 115–116
 - octahedral shear, 115
 - shear, 115–116
 - Stress relaxation, 118
 - Stress-field translation
 - condyle metabolism and, 107–109
 - description of, 103–105
 - mediolateral, 104–105
 - recording of, 109
 - Subchondral bone, in osteoarthritis, 37f, 39f, 39–41
 - Subchondral sclerosis, 40
 - Subnucleus caudalis, 6, 8
 - Suction cup effect, 124
 - Superficial zone protein, 125
 - Suprathreshold estimation, 80–83, 81f
 - Surface-active phospholipids, 124, 126–127
 - Sympathetic nervous system, 25
 - Synovial cells, 34
 - Synovial chondromatosis, 136f
 - Synovial joints
 - lubrication, 124–126
 - osteoarthritis and, 155
 - Synovitis, 159
- ## T
- Temporomandibular disorder pain
 - comorbid conditions effect on, 49–51, 51t
 - etiology of, 141
 - factors that affect, 52
 - fibromyalgia and, 49–50
 - migraine headache and, 50
 - persistence of, 51, 96
 - pharmacologic treatment of, 185–191
 - prognosis for, 51
 - progression of, 52f
 - signs and symptoms of, 47
 - sleep fragmentation as cause of, 61
 - Temporomandibular disorders
 - condition-specific measures for, 93
 - definition of, 13, 47
 - finite element analysis applications, 119–120
 - masticatory myofascial pain and, 23–24
 - mechanical, 95–96
 - overview of, 13–15
 - prevalence of, 47, 167
 - primary pain-related, 95

- Temporomandibular joint
 anatomy of, 168–169
 arthralgia of
 causes of, 123
 description of, 47
 intraoral appliances for, 53
 clicking of, 93
 development of, 168–169
 disc. *See* Articular disc.
 dynamic loading of, 102
 evolution of, 169–173
 finite element analysis of. *See* Finite element analysis.
 imaging of, 133–140
 immobilization of, 127
 load distribution in, 113
 locking of, 93
 lubrication of, 123–129
 osteoarthritis onset in, 101, 109
 shear loading in, 102
 static loading of, 102
 stress-field translation in, 103–105
 tractional forces in, 102–103
- Tension-type headaches, 62–63
- Testing algorithms, 80
- Thalamocortical nociceptive processing, 8
- Thalamus, 147f, 147–148
- Tissue engineering, 167–174
- Tissue inhibitors of metalloproteinase 1, 38, 109, 158
- Toll-like receptors, 12
- Tractional forces, 102–103
- Transcription factors, 36f
- Transforming growth factor beta, 178
- Transforming growth factor beta-1, 167
- Transient receptor potential receptors, 4
- Trauma
 masticatory myofascial pain secondary to, 22
 neuropathic pain associated with, 84, 86
- Treatment
 advances in, 165
 anticipated clinical applications of, 96–97
 classification of, 93–94
 comorbid pain conditions, 52–53
 etiology effects on, 91–92
 generic, 96
 goals of, 52
 interdisciplinary, 52–53
 multimodal plan of, 53
 pharmacologic. *See* Pharmacologic treatment.
 presenting condition and, matching between, 94
 rehabilitation model of, 92, 96
- Treatment responsiveness
 behavioral factors that affect, 95
 catastrophizing effects on, 95
 clustering effects on, 96–97
 comorbid pain conditions effect on, 95
 factors that affect, 94–96
 level of analysis effects on, 94
 measurement of, 92–96
 objective measures of, 93
 patient-reported outcomes, 93
 physical factors that affect, 95
 predictions about, 92
 self-report condition-specific measures of, 93
- Triangulation, 81, 82f
- Tricyclic antidepressants, 186
- Trigeminal brain complex, 6, 8
- Trigeminal brainstem nuclei, 146
- Trigeminal nociceptive pathways, 14
- Trigeminal somatosensory pathways, 7f
- Trigeminal tractotomy, 6
- Trigger points, 25
- TRPV1, 190
- Tumor necrosis factor- α , 4, 156–157, 161
- U**
- Unilateral mandibular hypoplasia, 119
- V**
- Vanilloid receptor 1. *See* TRPV1.
- Vascular endothelial growth factor, 38, 42, 157–158
- Ventroposterior nucleus, 8
- Vicious cycle theory, 23
- Viscoelasticity, 118
- Visual analog scales, 81
- Vi/Vc neurons, 13
- Voltage-gated calcium channels, 191
- von Mises stress, 115
- Voxel-based morphometry, 142, 149
- W**
- Wakefulness, 58
- Whiplash, 22
- White matter volume, 148–149
- Whole genome sequencing, 70, 72
- Wide dynamic range neurons, 6, 8, 10
- Widespread Pain Index, 49
- X**
- X-rays, 133